Core Viewpoint - BioPorto A/S has announced positive preliminary results from its U.S. adult NGAL Cutoff Study, which evaluates the performance of NGAL in assessing the risk of acute kidney injury (AKI) and plans to submit an FDA Pre-submission package by the end of Q1 2026 [1][2][3] Group 1: Study Results and Regulatory Strategy - The patient enrollment for the adult study was completed in October 2025, with database lock finalized in March 2026, showing positive results that support the primary endpoint [2] - The findings are consistent with previous studies conducted in the pediatric segment, which led to FDA clearance for the pediatric indication at the end of 2023, providing a strong foundation for BioPorto's regulatory strategy [2] - The planned Pre-submission will seek FDA feedback on the regulatory pathway and study protocols for the subsequent Validation Study [3] Group 2: Company Leadership and Milestones - BioPorto's Senior Medical Director expressed confidence in the results, indicating strong support for NGAL as a biomarker for identifying AKI risk in critically ill adults [3] - The CEO highlighted the analysis as a major milestone, emphasizing the importance of the Pre-submission step for designing the optimal Validation Study [4] - The announcement does not alter BioPorto's financial guidance as published on February 5, 2026 [4] Group 3: Company Overview and Product Focus - BioPorto is focused on in vitro diagnostics, aiming to improve patient management through actionable biomarkers, particularly in areas with significant unmet medical needs [8] - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and diagnosis of AKI, enabling earlier intervention and tailored patient management strategies [9] - BioPorto operates facilities in Copenhagen, Denmark, and Boston, MA, USA, and is listed on the Nasdaq Copenhagen stock exchange [10]